XPO1 and cancer: As an additional effect, the CRM1 inhibitors may sensitize resistant cancer cells for other drugs, e.g., as shown by Topoisomerase in multiple myeloma, which has to be localized in the nucleus in order to be sensitive for doxorubicin and etoposide treatment [117].